Popoviciu Mihaela-Simona, Salmen Teodor, Reurean-Pintilei Delia, Voiculescu Vlad, Pantea Stoian Anca
Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Medicina (Kaunas). 2025 Mar 20;61(3):548. doi: 10.3390/medicina61030548.
Elevated blood sugar poses an increasingly significant challenge to healthcare systems worldwide. We aimed to assess the efficacy of the SGLT-2i class in achieving metabolic control in patients with T2DM within a real-world standard-of-care regimen. A prospective analysis was conducted over 6 months including individuals receiving care in an outpatient department, with baseline assessments and follow-ups at 3 and 6 months. A total of 280 patients were assessed, with a mean age of 63.69 ± 9.16, 53.9% of which were males, with a mean DM duration of 9.06 ± 5.64 years, and a DM duration varying from 6 months to 24 years. Real-world evidence bridges the gap between guidelines and practice. It emphasizes the need to overcome clinical inertia in order to optimize patient outcomes and contributes to the body of evidence supporting the efficacy of fixed-dose SGLT-2i combinations in managing T2DM and associated comorbidities. We demonstrate the significant clinical and therapeutic impact of SGLT-2i in T2DM patients in a real-world setting. This class of medication not only positively influences glycemic and weight control but also reduces CV risk factors and visceral adiposity.
血糖升高对全球医疗保健系统构成了日益严峻的挑战。我们旨在评估在现实世界的标准治疗方案中，SGLT-2i类药物在实现2型糖尿病（T2DM）患者代谢控制方面的疗效。进行了为期6个月的前瞻性分析，纳入在门诊接受治疗的患者，在基线进行评估，并在3个月和6个月时进行随访。共评估了280例患者，平均年龄为63.69±9.16岁，其中53.9%为男性，平均糖尿病病程为9.06±5.64年，糖尿病病程从6个月到24年不等。真实世界证据弥合了指南与实践之间的差距。它强调需要克服临床惰性以优化患者结局，并为支持固定剂量SGLT-2i联合用药治疗T2DM及其相关合并症疗效的证据体系做出贡献。我们证明了在现实世界中，SGLT-2i对T2DM患者具有显著的临床和治疗影响。这类药物不仅对血糖和体重控制产生积极影响，还能降低心血管危险因素和内脏脂肪。
